Anti-resorptive medication use is not associated with acute cardiovascular risk: An observational study: Anti-resorptive medication and cardiovascular risk.

Bliuc, D; Tran, T; Chen, W; Alarkawi, D; Alajlouni, DA; Blyth, F; March, L; Blank, RD; Center, JR

Anti-resorptive medication use is not associated with acute cardiovascular risk: An observational study: Anti-resorptive medication and cardiovascular risk.

Bliuc, D Tran, T Chen, W Alarkawi, D Alajlouni, DA Blyth, F March, L Blank, RD Center, JR

Permalink

Publisher:: The Endocrine Society
Publication Type:: Journal Article
Citation:: J Clin Endocrinol Metab, 2022, pp. dgac669
Issue Date:: 2022-11-21

Closed Access

	Filename	Description	Size
	O_JCEM 2023.pdf		732.35 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Bliuc, D
dc.contributor.author	Tran, T
dc.contributor.author	Chen, W
dc.contributor.author	Alarkawi, D
dc.contributor.author	Alajlouni, DA
dc.contributor.author	Blyth, F
dc.contributor.author	March, L
dc.contributor.author	Blank, RD
dc.contributor.author	Center, JR
dc.date.accessioned	2023-03-13T06:17:00Z
dc.date.available	2022-11-15
dc.date.available	2023-03-13T06:17:00Z
dc.date.issued	2022-11-21
dc.identifier.citation	J Clin Endocrinol Metab, 2022, pp. dgac669
dc.identifier.issn	0021-972X
dc.identifier.issn	1945-7197
dc.identifier.uri	http://hdl.handle.net/10453/167151
dc.description.abstract	BACKGROUND: Bisphosphonates have been reported to be cardio-protective in some, but not all studies. It is unknown whether denosumab use protects against cardiovascular events (CVE). OBJECTIVES: To determine whether oral bisphosphonate (oBP) or denosumab (Dmab) use is associated with CVE in persons with incident fracture. DESIGN: 267,357 participants from The Sax's Institute 45 and Up Study followed (2005/2009 - 2017). Questionnaire data were linked to hospital admissions (Admitted Patients Data Collection -APDC),1 Pharmaceutical Benefits Scheme (PBS)2 and stored securely3. Fractures, CVEs and comorbidities were identified from APDC and medication from PBS. SETTING: Population-based cohort from NSW, Australia. PARTICIPANTS: Individuals aged 45 + with an incident fracture. oBP and Dmab users were matched to NoRx by propensity scores. MAIN OUTCOME MEASUREMENTS: Association between oBP and Dmab with CVE (acute myocardial infarction, unstable angina, cerebro-vascular accident and transient ischaemic attack) was determined using a stratified Cox's proportional hazards model. RESULTS: There were 880 pairs of oBP and noRx (616 women) and 770 pairs of Dmab and NoRx (615 women) followed for ∼4.3 years. CVE risk was similar for oBP and NoRx [women: HR 0.88 (95% CI, 0.65-1.18) and men: 1.07 (95% CI, 0.72-1.57)]. Similar findings were obtained for Dmab [women: 1.08 (95% CI, 0.78-1.50) and men: 1.55 (95% CI, 0.96-2.48)]. CONCLUSIONS: oBP and Dmab use was not associated with CVE.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	The Endocrine Society
dc.relation.ispartof	J Clin Endocrinol Metab
dc.relation.isbasedon	10.1210/clinem/dgac669
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1103 Clinical Sciences, 1114 Paediatrics and Reproductive Medicine
dc.subject.classification	Endocrinology & Metabolism
dc.title	Anti-resorptive medication use is not associated with acute cardiovascular risk: An observational study: Anti-resorptive medication and cardiovascular risk.
dc.type	Journal Article
utslib.location.activity	United States
utslib.for	1103 Clinical Sciences
utslib.for	1114 Paediatrics and Reproductive Medicine
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology
pubs.organisational-group	/University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering
utslib.copyright.status	closed_access	*
dc.date.updated	2023-03-13T06:16:59Z
pubs.publication-status	Published online

Abstract:

BACKGROUND: Bisphosphonates have been reported to be cardio-protective in some, but not all studies. It is unknown whether denosumab use protects against cardiovascular events (CVE). OBJECTIVES: To determine whether oral bisphosphonate (oBP) or denosumab (Dmab) use is associated with CVE in persons with incident fracture. DESIGN: 267,357 participants from The Sax's Institute 45 and Up Study followed (2005/2009 - 2017). Questionnaire data were linked to hospital admissions (Admitted Patients Data Collection -APDC),1 Pharmaceutical Benefits Scheme (PBS)2 and stored securely3. Fractures, CVEs and comorbidities were identified from APDC and medication from PBS. SETTING: Population-based cohort from NSW, Australia. PARTICIPANTS: Individuals aged 45 + with an incident fracture. oBP and Dmab users were matched to NoRx by propensity scores. MAIN OUTCOME MEASUREMENTS: Association between oBP and Dmab with CVE (acute myocardial infarction, unstable angina, cerebro-vascular accident and transient ischaemic attack) was determined using a stratified Cox's proportional hazards model. RESULTS: There were 880 pairs of oBP and noRx (616 women) and 770 pairs of Dmab and NoRx (615 women) followed for ∼4.3 years. CVE risk was similar for oBP and NoRx [women: HR 0.88 (95% CI, 0.65-1.18) and men: 1.07 (95% CI, 0.72-1.57)]. Similar findings were obtained for Dmab [women: 1.08 (95% CI, 0.78-1.50) and men: 1.55 (95% CI, 0.96-2.48)]. CONCLUSIONS: oBP and Dmab use was not associated with CVE.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/167151